The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance
Publication year: 2014
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety conditions, and presents the necessary caveats relevant to the use of this new drug for which Phase III clinical trial data are not yet available.
Cost-Benefit Analysis, Tuberculosis, Multidrug-Resistant/drug therapy, Drug Therapy, Combination, Nitroimidazoles/therapeutic use, Treatment Outcome, Antitubercular Agents/therapeutic use, Tuberculosis, Pulmonary/drug therapy, Clinical Trials as Topic, Nitroimidazoles/economics, Antitubercular Agents/economics